Abstract: The invention relates to a novel process for preparing an optically pure PPI having a sulfinyl structure using a chiral zirconium complex or a chiral hafnium complex.
Type:
Grant
Filed:
December 3, 2003
Date of Patent:
November 18, 2008
Assignee:
Nycomed GmbH
Inventors:
Bernhard Kohl, Bernd Müller, Ralf Steffen Weingart
Abstract: The invention relates to a process for the synthesis of compounds of the formula 1-a and compounds of the formula 1-b. The compounds of the formula 1-a and the compounds of the formula 1-b, in which the substituents R1, R2, R3, and Ar have the meanings indicated in the description, are valuable intermediates for the preparation of pharmaceutically active compounds.
Type:
Application
Filed:
June 20, 2006
Publication date:
November 13, 2008
Applicant:
NYCOMED GmbH
Inventors:
Maria Vittoria Chiesa, Andreas Palmer, Wilm Buhr, Peter Jan Zimmermann, Christof Brehm, Wolfgang-Alexander Simon, Stefan Postius, Wolfgang Kromer, Antonio Zanotti-Gerosa
Abstract: A topical pharmaceutical preparation for administering a slightly soluble PDE4 inhibitor is described. A surprisingly good systemic bioavailability is observed with this dosage form.
Abstract: Compounds of a certain formula (I) in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity.
Type:
Application
Filed:
May 24, 2006
Publication date:
October 23, 2008
Applicant:
NYCOMED GmbH
Inventors:
Klaus Pekari, Mathias Schmidt, Thomas Bar, Thomas Beckers, Petra Gimmnich
Abstract: The invention relates to the combined use of a PDE4 inhibitor and a conventional NSAID in the treatment of an inflammatory disease and/or an inflammation-associated disorder while minimizing gastrointestinal side effects, such as gastric erosions and ulcer, which are frequently associated with the use of conventional NSAIDs. A preferred PDE 4 inhibitor for this combination is roflumilast or a derivative thereof. A preferred conventional NSAID for this combination is diclofenac or a derivative thereof.
Abstract: The invention relates to an oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles and their salts, which comprises the active compound together with tablet disintegrants and is provided with a film coating customary per se for sustained-release compositions.
Abstract: The invention describes the use of a PDE4 inhibitor in combination with BH4 or a BH4 derivative for the prevention and/or treatment of respiratory diseases.
Type:
Application
Filed:
May 8, 2006
Publication date:
September 11, 2008
Applicant:
NYCOMED GmbH
Inventors:
Christian Hesslinger, Christian Schudt, Degenhard Marx, Clemens Braun
Abstract: Compounds of formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meaning indicated in the description, are novel effective PDE4 inhibitors.
Abstract: Compounds of a certain formula (I) in which R1, R2, R3, R31, R4, R5, R51, R6 and R7 have the meanings indicated in the description, are novel effective PDE4 inhibitors.
Type:
Application
Filed:
March 9, 2006
Publication date:
September 4, 2008
Applicant:
NYCOMED Gmbh
Inventors:
Ulrich Kautz, Beate Schmidt, Dieter Flockerzi, Maria Vittoria Chiesa, Armin Hatzelmann, Christof Zitt, Johannes Barsig, Degenhard Marx, Hans-Peter Kley
Abstract: The invention relates to salts of 6-heteroaryl substituted hexahydrophenanthridine PDE4-inhibiting compounds, which can be used in the pharmaceutical industry for the production of pharmaceutical compositions for use, e.g., in treatment of airway disorders.
Type:
Application
Filed:
March 1, 2006
Publication date:
August 14, 2008
Applicant:
NYCOMED GmbH
Inventors:
Ulrich Kautz, Matthias Webel, Christian Scheufler, Rolf-Peter Hummel
Abstract: Compounds of a certain formula (I) in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors.
Type:
Application
Filed:
March 14, 2006
Publication date:
July 24, 2008
Applicant:
Nycomed GmbH
Inventors:
Thomas Maier, Thomas Bar, Thomas Beckers, Astrid Zimmermann, Siegfried Schneider, Volker Gekeler
Abstract: The invention relates to an oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles and their salts, which comprises the active compound together with tablet disintegrants and is provided with a film coating customary per se for sustained-release compositions.
Abstract: The invention relates to compounds of formula 1 and formula 10 and to compositions comprising these compounds and methods of treating gastrointestinal disorders by administering these compounds.
Type:
Application
Filed:
December 12, 2007
Publication date:
June 19, 2008
Applicant:
NYCOMED GmbH
Inventors:
Bernhard Kohl, Bernd Muller, Dieter Haag, Wolfgang-Alexander Simon, Karl Zech, Michael David, Oliver Von Richter, Felix Huth
Abstract: The present invention relates to the field of pharmaceutical technology and describes a novel pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient, in particular an acid-labile proton pump inhibitor. The invention also relates to processes for producing the suspension. The suspension is particularly suitable for administering acid-labile active ingredients to people who have difficulty taking solid dosage forms such as tablets or capsules.
Abstract: Lyophilized pantoprazole preparations which are obtainable by freeze-drying of an aqueous solution of pantoprazole, ethylenediamine tetraacetic acid and/or a suitable salt thereof, and sodium hydroxide and/or sodium carbonate are disclosed. The preparations have advantageous properties when reconstituted for injection.
Abstract: The invention relates to novel pyrrolodihydroisoquinoline derivatives which are efficacious inhibitors of cellular (hyper)proliferation and/or inducers of apoptosis in cancer cells.
Type:
Application
Filed:
January 11, 2006
Publication date:
March 13, 2008
Applicant:
NYCOMED GMBH
Inventors:
Matthias Vennemann, Thomas Bar, Juergen Braunger, Volker Gekeler, Petra Gimmnich, Paola Ciapetti, Jean-Marie Contreras, Camille Wermuth
Abstract: The compounds of formula I in which R1, R2, R3, R31, R4, R5, R6 and R7 have the meanings as indicated in the description, are novel effective PDE4 inhibitors.